eTheRNA expands R&D capacity   

mRNA technology discovery and development company, eTheRNA immunotherapies has announced it has relocated its R&D group to a larger site in Belgium.  

The company has moved its R&D facility to the Zwijnaarde Science Park in Gent, Belgium, which features a cluster of biotech companies and includes laboratories and allied services. The move has been made to increase eTheRNA’s R&D capacity and enable its research departments to enhance their investigations on a variety of mRNA and lipid nanoparticles for R&D applications. The company hopes that this will result in improved control and faster production cycles.  

Official comments 

 Stefaan De Koker, eTheRNA VP of Discovery, said:  “We are excited that this move gives us the opportunity to upgrade our R&D facility, allowing us to expand our activities and accomplish the ambitious goals that we have set for our research and development programs. This new facility makes it possible for us to strengthen our capabilities across the board, and we intend to leverage it fully to achieve our company milestones.” 


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free